Ann: Lumos Receives US$400k Phase 1 Milestone from Hologic, page-21

Market is mostly right, and even if it’s wrong (undervalued) it does not remain wrong for too long, The way everything is going with Lumos , I am assuming FebriDx is a commercially failed product and it’s clearly reflected on LDX price action.
If there was even an hint of it getting successful on market , say in one year time ,its price wouldn’t be sitting at where it is now. Also there are many red flags *management not buying , no new distribution/sales news etc
I researched good amount and believed in FebriDx and invested heavily on it and have suffered substantial losses. I still wish FebriDx would be a success but I don’t see it happening.